Valuation
- Market cap
- 31,644,000
- Revenue TTM
- $80,280,000
- Net income TTM
- $-38,830,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -48.37%
- Debt to equity
- -3.53
Trading
- Volume
- 129,100
- Avg volume
- 190,400
- Day's range
- $0.76 – $0.84
- Shares out
- 36,795,000
- Stochastic %K
- 43%
- Beta
- 1.46
- Analysts
- Moderate Buy
- Price target
- $2.00
Company profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to a...
Show more
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 484 320 2930
- Website
- https://www.telabio.com
- Address
- 1 Great Valley Parkway, Suite 24, Malvern, United States
Latest news
No headlines yet.
